Antibody mass escalation study in patients with castration resistant prostate cancer using (111)I-J591: Lesion detectability and dosimetric projections for (90)Y radioimmunotherapy

BACKGROUND: J591, a monoclonal antibody that targets the external domain of the prostate specific membrane antigen (PSMA), has potential as an agent for radioimmunotherapy. A pilot trial was carried out in patients with prostate cancer using repetitive administrations of escalating masses of J591. A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pandit-Taskar, Neeta, O’Donoghue, Joseph A., Morris, Michael J, Wills, Eze A., Schwartz, Lawrence H., Gonen, Mithat, Scher, Howard I., Larson, Steven M., Divgi, Chaitanya R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2766795/
https://ncbi.nlm.nih.gov/pubmed/18552139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.049502
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi